WeChat· 药精通Bio·· 2026-08-21PickScore77
Moderna and Merck's Personalized mRNA Cancer Vaccine intismeran autogene with Keytruda Succeeds in INTerpath-001 Trial
In brief
On August 19, 2026, Moderna and Merck jointly announced that the INTerpath-001 trial of the personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) combined with Keytruda (pembrolizumab) succeeded. The original article reports Moderna's stock surged 177% that day, calls it an "extraordinary milestone," and says the company's next three years hinge on converting this result into sustainable cash flow.
Why it matters
Reports the key INTerpath-001 success so readers can assess the combination's relevance to mRNA cancer vaccines.
Source: WeChat · mp.weixin.qq.com